0000905148-24-002511.txt : 20240904 0000905148-24-002511.hdr.sgml : 20240904 20240904203343 ACCESSION NUMBER: 0000905148-24-002511 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240830 FILED AS OF DATE: 20240904 DATE AS OF CHANGE: 20240904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schorno Dean L CENTRAL INDEX KEY: 0001509688 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29889 FILM NUMBER: 241279304 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RIGEL PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001034842 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943248524 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-624-1100 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-08-30 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001509688 Schorno Dean L RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true EVP & Chief Financial Officer false Employee Stock Option (right to buy) 24.2 2024-08-30 4 A 0 10000 0 A 2030-02-06 Common Stock 10000 10000 D The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. The option was fully vested on August 30, 2024, the date the determination was made that the performance metric had been met. /s/ Raymond Furey (Attorney-in-Fact) 2024-09-04